-- RBCキャピタル・マーケッツのストラテジストは金曜日のレポートで、原油価格が1バレル100ドルを突破し、中東情勢の緊迫化によって世界の供給見通しが逼迫したことを受け、先週の米国の石油・ガス探査・生産(E&P)関連株が上昇したと述べた。 RBCのアナリストによると、石油比重の高いE&P株は同期間に5%上昇し、ガス比重の高いE&P株は2%上昇した。大型株は5%、中小型株は3%上昇した。 エネルギーETFのXOPは、WTI原油価格の10%上昇とヘンリーハブ天然ガス価格の6%上昇に連動し、5%上昇した。 RBCは、米国のE&P企業の第1四半期決算は現時点で「予想をやや上回る」ものの、活動の広範な回復を示す兆候は限定的であると指摘した。 同行は、パーミアン盆地の掘削リグ数がわずかに増加していることを指摘し、これは掘削活動の広範な加速というよりも、ガス輸送能力の制約が一因であると分析した。 一方、世界の原油市場は、停滞する外交努力やホルムズ海峡における混乱への懸念など、地政学的リスクの継続によって支えられた。 RBCは、地域情勢の悪化の可能性に関する報道がリスクプレミアムを押し上げ、ブレント原油価格に連動するセンチメントを上昇させたと指摘した。 同行はまた、UAEがOPECの生産能力規律から事実上離脱したことで、世界の供給力学に構造的な変化が生じていることにも言及した。これにより、OPECの政策手段から相当量の余剰生産能力が排除されると予想される。 RBCは、UAEのOPEC離脱により、サウジアラビアは市場の安定維持においてより大きな負担を負うことになると述べた。
Related Articles
Research Alert: CFRA Maintains Hold Rating On Shares Of Moderna, Inc. After Q1 Earnings
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After reviewing Q1 results, we up our target to $48 from $39, based on our NPV analysis. We widen our 2026 LPS view to -$7.95 from -$7.16 and keep our 2027 LPS view at -$4.82. MRNA reported a strong Q1, exceeding revenue expectations and demonstrating significant Y/Y growth. During the analyst call, management highlighted key regulatory approvals in Europe for its respiratory vaccine portfolio and oncology pipeline advancements, which we find encouraging. Despite a GAAP net loss widened by a one-time litigation settlement, underlying financial discipline and cost reduction efforts are noteworthy. Yet, revenue guidance for Q2 is relatively low at $50M-$100M (CFRA: $92M), which points to a 65%-30% Y/Y deceleration (CFRA: 35%) but also signals a significant swing Q/Q after the company recorded $153M in sales in Q1. While we think the progress in the oncology pipeline with the partnership with Merck & Co. (MRK 112 ****) is promising and progressing well, we continue to view MRNA as a wait and see story.
Research Alert: CFRA Maintains Hold Rating On Shares Of Ge Healthcare Technologies Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $65 from $87, based on 11.8x our 2027 EPS estimate of $5.51, a sharp discount to the stock's average forward P/E of 18.1x. We cut our 2026 adjusted EPS estimate to $4.86 from $4.96, which stands at the lower end of the reduced guidance range of $4.80-$5.00 (vs. previous $4.95-$5.15). GEHC achieved Q1 organic revenue growth of 2.9% Y/Y, which was at the high end of its expectations. Yet profitability metrics were disappointing with adjusted EPS of $0.99 missing expectations, and the adjusted EBIT margin declining 150 bps Y/Y. This was primarily due to a discrete supplier issue in the PDx business and an unexpected increase in inflationary costs. As a result, GEHC lowered its profit and cash flow outlook, which we view as a prudent move. Strategically, we think GEHC is advancing a strong innovation pipeline, has completed the acquisition of Intelerad, and has announced a reorganization to combine its Imaging and AVS segments into a new segment, which has the potential to accelerate growth.
Research Alert: CFRA Maintains Hold Rating On Shares Of Lennox International Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target to $569 from $559, 21.4x our 2027 EPS estimate (down to $26.57 from $26.62; our 2026 estimate down to $24.14 from $24.51), near LII's three- and five-year historical forward averages of 21.9x and 20.6x, respectively. We think LII faces material near-term operational challenges from residential market softness, escalating tariff-driven cost inflation (~5% vs. prior ~2.5% guidance), and margin compression in its Home Comfort Solutions segment (390-bp decline to 13.3% in Q1). However, these concerns are substantially mitigated by the Building Climate Solutions segment's exceptional performance (38% revenue growth, 300-bp margin expansion to 19.7% in Q1), significantly improved operating cash flow ($16.1M vs. -$35.8M Y/Y) due to inventory normalization. We note an antitrust class action lawsuit, filed in March, alleging price-fixing among HVAC equipment manufacturers since January 2020, posing an additional risk to LII's financial and reputational standing.